CriticalDirect oral anticoagulants (factor Xa inhibitors)×Direct thrombin inhibitor
Updated · Methodology
Mechanism
Apixaban inhibits factor Xa; dabigatran inhibits thrombin. Additive anticoagulation with no therapeutic benefit and high risk of major bleeding.
Symptoms
Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage, gross haematuria with renal colic, spontaneous retroperitoneal haematomas. Symptoms may appear within days of co-prescription.
Management
The combination is not prescribed. When switching DOACs, stop the first and start the second at the next scheduled dose. Overlap is only acceptable via a parenteral anticoagulant when bridging is needed.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Eliquis (apixaban) prescribing information (2021)– ; DailyMed setid e9481622-7cc6-418a-acb6-c5450daae9b0
- AEMPS: Ficha técnica: Dabigatrán (nº registro 86841), sección 4.3 (2026)– AEMPS, CIMA, nº registro 86841, revisión 05/2026, sección 4.3
- EMA: Ficha técnica: Apixabán (EU/1/11/169), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 111691009 (EU/1/11/169), sección 4.3, consultado 10/2026